EichorEICHOR
Condition: Uterine Endometrial Cancer Synced from ClinicalTrials.gov · August 05, 2026

Recruiting studies: Uterine Endometrial Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871Sentinel Node Biopsy in Endometrial Cancer
Phase 3 · 19 location(s) · Queensland Centre for Gynaecological Cancer · NCT04073706Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT07062016Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1/Phase 2 · 60 location(s) · AstraZeneca · NCT05797168A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Gra
Phase 2 · 22 location(s) · Centre Leon Berard · NCT03624244Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Phase 1/Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06040970Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations
Phase N/A · 2 location(s) · MiMARK Diagnostics, S.L. · NCT07148154GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Phase 2/Phase 3 · 2 location(s) · Xiaojun Chen · NCT05316935A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
Phase 2/Phase 3 · 14 location(s) · Leiden University Medical Center · NCT05255653Early Detection of Endometrial/Ovarian Cancer and Hereditary Predisposition of These Cancers
NA · 2 location(s) · McGill University · NCT04891029Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 · 17 location(s) · SystImmune Inc. · NCT06293898Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT07318324Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemothera
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04997096A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Day One Biopharmaceuticals, Inc. · NCT05377996A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Phase 1 · 13 location(s) · Boehringer Ingelheim · NCT07306559A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Phase 1 · 6 location(s) · Sutro Biopharma, Inc. · NCT07227168A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Kivu Bioscience Inc. · NCT07229313Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05247268A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · 62 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Ute
Phase 3 · 171 location(s) · BioNTech SE · NCT06340568A Study of LY4175408 in Participants With Advanced Cancer
Phase 1 · 27 location(s) · Eli Lilly and Company · NCT07046923Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · 409 location(s) · National Cancer Institute (NCI) · NCT05256225Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
Phase N/A · 2 location(s) · Aesculap AG · NCT06024109Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Phase 1 · 18 location(s) · Xencor, Inc. · NCT06276491Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT07675967Activity Coaching During Pelvic Radiation Therapy
NA · 4 location(s) · Inova Health Care Services · NCT06746428A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.